Vasomotor Rhinitis

01/01/2009 - "Intranasal azelastine hydrochloride (Astelin, Meda Pharmaceuticals, Somerset, NJ, USA) is a first-line treatment for allergic and non-allergic vasomotor rhinitis with well-established therapeutic efficacy and safety. "
11/01/2013 - "Total vasomotor rhinitis symptoms scores were substantially reduced in the azelastine-treated subjects compared with the control group. "
03/01/2001 - "The present study demonstrates the efficacy of azelastine nasal spray in the treatment of vasomotor rhinitis. "
03/01/2001 - "We performed a multicenter randomized double-blind placebo-controlled study of the efficacy and tolerance of azelastine nasal spray in 89 adult patients with vasomotor rhinitis (confirmed by negative Phadiatop). "
12/01/2019 - "Azelastine is a histamine H1 antagonist indicated for vasomotor rhinitis. "

01/01/2017 - " study evaluates the clinical efficacy of the inhalation of a natural compound (Narivent® nasal spray) in chronic vasomotor rhinitis. "
01/01/2006 - "Of 35 patients with hypertrophic lower turbinates due to vasomotor rhinitis, 20 were treated twice daily with FP aqueous nasal spray (200 microg/day) for 3 months continuously and 15 were treated with placebo vehicle as a control group. "
01/01/2006 - "To assess the efficacy of FP aqueous nasal spray treatment in lower turbinate hypertrophy due to vasomotor rhinitis using CT. "
01/01/2006 - "Fluticasone propionate (FP) aqueous nasal spray was objectively found to be effective and safe for the treatment of lower turbinate enlargement in patients with vasomotor rhinitis. "
03/01/2001 - "The present study demonstrates the efficacy of azelastine nasal spray in the treatment of vasomotor rhinitis. "

08/15/2009 - "Interpreting this information allows one to conclude that antihistamines may be potentially effective agents in vasomotor rhinitis, and are more likely to be so when administered intranasally, despite the fact that data documenting this beneficial effect are sparse."
08/15/2009 - "The role of antihistamines in the treatment of vasomotor rhinitis."
11/01/2007 - "Intranasal antihistamine therapy represents an effective mode of drug delivery in patients with allergic and nonallergic vasomotor rhinitis and is an important option for rhinitis therapy, particularly if rapid symptom relief is required or if congestion is a major symptom. "
01/01/2022 - "Based on the results of our studies, the proposed treatment regimen for vasomotor rhinitis with the local antihistamine medicine Palada NS can be recommended for patients with vasomotor rhinitis, both with and without COVID-19 infection."
01/01/2022 - "The aim of our study was to evaluate the effectiveness of treatment with the local antihistamine medicine Palada NS in patients with vasomotor rhinitis who have had COVID-19 infection (6 months after transfer) and have not. "

12/01/1988 - "Additionally, capsaicin, which in high concentration selectively blocks sensory C-fibers, was found to be effective in treatment of hyperreactive rhinopathy (vasomotor rhinitis). "
02/01/1999 - "The results of this preliminary study lead us to consider that an imbalance in the autonomic innervation of the mucosa of the middle ear may play a role in the aetiology of SOM as in vasomotor rhinitis, and capsaicin may be an alternative in the treatment."
01/01/2014 - "Intranasal capsaicin in management of nonallergic (vasomotor) rhinitis."
07/01/1997 - "Wolf and others have demonstrated in human subjects that vasomotor rhinitis can be blocked up to 1 year by a series of intranasal capsaicin applications. "
07/01/1997 - "Its antidromic effects have been implicated in vasomotor rhinitis and can be blocked by topical intranasal capsaicin application. "

01/01/2012 - "The objective of this work was to study the feasibility and effectiveness of the cavitational low-frequency ultrasound treatment of vasomotor rhinitis in combination with the application of topical corticosteroids. "
01/01/2012 - "The data obtained indicate that the low-frequency cavitational treatment of intranasal mucosa in combination with the application of topical corticosteroids may be recommended as an efficatious method for the treatment of vasomotor rhinitis."
08/15/2009 - "The treatment of vasomotor rhinitis with intranasal corticosteroids."
03/01/2009 - "Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment."
01/01/1964 - "[OUR EXPERIENCE ON TREATMENT OF VASOMOTOR RHINITIS WITH LOCAL INFILTRATIONS OF CORTICOSTEROIDS]."

11/01/1986 - "A trial of intranasal Atrovent versus placebo in the treatment of vasomotor rhinitis."
12/01/1983 - "A therapeutical trial with ipratropium is appropriate in the management of severe rhinorrhoea in patients with vasomotor rhinitis."
06/01/1990 - "In conclusion, the vasomotor rhinitis increases the systemic absorption of nasally administered ipratropium bromide, but the small increase in the absorption is not likely to have any clinical consequences."
06/01/1990 - "Plasma concentrations of nasally administered ipratropium bromide were analyzed in 10 subjects suffering from severe vasomotor rhinitis and 10 age-sex matched control subjects. "
06/01/1990 - "Vasomotor rhinitis and the systemic absorption of ipratropium bromide."

01/01/1983 - "Twelve patients entered a long-term study of budesonide treatment in vasomotor rhinitis. "
12/01/1984 - "Intranasal budesonide (200 to 400 micrograms/day) relieves nasal symptoms in patients with seasonal allergic, perennial allergic and vasomotor rhinitis. "
01/01/1983 - "Long-term treatment with budesonide in vasomotor rhinitis."
11/07/2023 - "The Efficacy of Budesonide, Levocabastine, and Their Combination in Treatment of Vasomotor Rhinitis."
12/05/2018 - "Method: One hundred and twenty vasomotor rhinitis patients were randomly divided into three groups including budesonide group, azelastine group, and budesonide and azelastine group with 40 cases in each. "

10/01/2003 - "Interestingly, nasal turbinates obtained from patients suffering from nonallergic rhinitis (vasomotor rhinitis) were also found to release eotaxin-2/CCL24 both spontaneously and following cytokine stimulation with IL-4 and IFN-gamma being major inducers of this cytokine. "
01/01/2004 - "While clinical studies of azelastine have demonstrated that this drug is highly efficacious in the treatment of all the symptoms of vasomotor rhinitis, mechanistic studies have demonstrated that azelastine has potent anti-inflammatory effects (in particular attenuation of the expression and synthesis of pro-inflammatory cytokines, leukotrienes, and cell adhesion molecules), which are likely to contribute to its clinical efficacy. "
01/01/2014 - "Our follow-up studies indicated that the nonselective inhibition of cytokine induced pSTAT3 and pSTAT1 activation by G-alpha stimulatory subunit-coupled G-protein-coupled receptor agonists, and forskolin was likely due to cyclic adenosine monophosphate-mediated up-regulation of suppressors of cytokine signaling 3. Azelastine, an H1 receptor antagonist approved for the treatment of seasonal allergic rhinitis, nonallergic vasomotor rhinitis, and ocular conjunctivitis, was subsequently confirmed as a selective inhibitor of IL-6-induced pSTAT3 activation that also reduced the growth of HNSCC cell lines. "
03/01/2003 - "Azelastine has established antiallergic and anti-inflammatory effects that are unrelated to H1-receptor antagonism, including inhibitory effects on the synthesis of leukotrienes, kinins, and cytokines; the generation of superoxide free radicals; and the expression of the intercellular adhesion molecule 1. Azelastine is available in the United States as a nasal spray formulation (Astelin) and is approved for treatment of seasonal allergic rhinitis and nonallergic vasomotor rhinitis. "

01/01/2004 - "While clinical studies of azelastine have demonstrated that this drug is highly efficacious in the treatment of all the symptoms of vasomotor rhinitis, mechanistic studies have demonstrated that azelastine has potent anti-inflammatory effects (in particular attenuation of the expression and synthesis of pro-inflammatory cytokines, leukotrienes, and cell adhesion molecules), which are likely to contribute to its clinical efficacy. "
03/01/2003 - "Azelastine has established antiallergic and anti-inflammatory effects that are unrelated to H1-receptor antagonism, including inhibitory effects on the synthesis of leukotrienes, kinins, and cytokines; the generation of superoxide free radicals; and the expression of the intercellular adhesion molecule 1. Azelastine is available in the United States as a nasal spray formulation (Astelin) and is approved for treatment of seasonal allergic rhinitis and nonallergic vasomotor rhinitis. "

10/01/1983 - "A similar effect on the nasal mucosa has been suggested as providing an explanation for the clinical effect of topically administered glucocorticoids in the treatment of nasal disorders such as allergic and vasomotor rhinitis. "
11/07/2023 - "Relevant studies have demonstrated that glucocorticoids and antihistamines, such as budesonide and azelastine, are effective in the treatment of vasomotor rhinitis, with their combined use being more effective than that of a single drug. "

01/01/1989 - "The efficacy of laser therapy of vasomotor rhinitis became optimal on irradiation day 6 or 7 and reached a maximum on day 10."
09/01/1990 - "[Functional methods of study in the evaluation of the effectiveness of laser therapy of vasomotor rhinitis and some forms of prosopalgia]."
01/01/2013 - "[The complications of laser surgery for the treatment of chronic vasomotor rhinitis]."
05/01/1991 - "Magnet-laser therapy was used to treat vasomotor rhinitis in 90 patients. "
01/01/1989 - "[Indicators of the activity of the immune system during laser therapy of vasomotor rhinitis]."

10/01/1958 - "[Study on therapy of vasomotor rhinitis]."
03/01/2010 - "Therapy should be based on the presenting symptoms of vasomotor rhinitis. "
01/01/2008 - "[Haloinhalation therapy of patients with allergic and vasomotor rhinitis]."
01/01/2002 - "The above vegetative shifts dictate the necessity of vegetotropic medication inclusion into combined therapy of vasomotor rhinitis."
09/01/2000 - "Different modalities of turbinate reduction procedures are available for treatment of vasomotor rhinitis not responding to appropriate medical therapy. "

04/01/1984 - "This cryotherapy technique provides significantly improved results in the treatment of vasomotor rhinitis when proper patient selection and technique are utilized."
04/01/1984 - "Cryotherapy for chronic vasomotor rhinitis: technique and patient selection for improved results."
11/11/1985 - "This article reviews the clinical and pathological features, differential diagnosis, and management of vasomotor rhinitis and reports a study of 110 patients treated between 1979 and 1983 by the application of cryotherapy to the mucosa overlying the inferior turbinate bones."
04/02/1982 - "Experience with cryotherapy of vasomotor rhinitis is reported. "
06/01/1977 - "Cryotherapy as a method of treatment in allergic and vasomotor rhinitis."

01/01/2008 - "The results of placebo-controlled randomized trial of effectiveness of haloinhalation treatment with application of individual inhaler Haloneb in 125 patients with allergic and vasomotor rhinitis demonstrated high efficacy of the method. "

01/01/2000 - "The conclusion is made that low-energy laser radiation is effective in correction of microcirculatory disorders and tissue mechanisms of homeostasis in children with neurovegetative vasomotor rhinitis."
01/01/2000 - "Turbinated bone's mucosa of 46 children aged 6 to 15 years was exposed to radiation of low-energy laser for neurovegetative vasomotor rhinitis. "
01/01/2000 - "[Correction of microcirculatory disorders with low-energy laser radiation in children with vasomotor rhinitis]."
09/01/1977 - "[Endonasal Ar+-laser beam guide system and first clinical application in vasomotor rhinitis (author's transl)]."
08/01/1986 - "The histological findings after argon-ion-laser-carbonization on the respiratory mucosa of the lower turbinates in vasomotor rhinitis are described directly after laser treatment and 6 years later. "